Clinical Trial Update: Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for intralymphatic allergen-specific immunotherapy shows safety and efficacy data from Phase 2 and Phase 3 studies in allergic rhinitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Intralymphatic allergen-specific immunotherapy

Snippet

Sponsor: Karolinska Institutet | Conditions: Allergic Rhinitis | Phase 2, Phase 3 | Status: COMPLETED